PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

被引：0

作者：

Garcia Campelo, M. R. ^{[1
]}

Zhou, C. ^{[2
]}

Ramalingam, S. S. ^{[3
]}

Lin, H. M. ^{[4
]}

Kim, T. M. ^{[5
]}

Riely, G. J. ^{[6
]}

Mekhail, T. ^{[7
]}

Nguyen, D. ^{[8
]}

Biber, J. ^{[9
]}

Romero, H. ^{[4
]}

Goodman, E. ^{[4
]}

Popat, S. ^{[10
,11
]}

Janne, P. A. ^{[12
]}

机构：

[1] Complejo Hosp Univ A Coruna, La Coruna, Spain

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Emory Univ, Atlanta, GA USA

[4] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] AdventHealth, Orlando, FL USA

[8] City Hope Natl Med Ctr, Los Angeles, CA USA

[9] Xcenda LLC, Carrollton, TX USA

[10] Royal Marsden Hosp, London, England

[11] Inst Canc Res, London, England

[12] Dana Farber Canc Inst, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

non-small cell lung cancer; exon20; insertion; patient-reported outcomes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.02-17

引用

页码：S487 / S488

页数：2

共 50 条

[21] A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib
Morton-Gittens, Jamie
Pipalia, Nisarg
Liu, Hongxiang
Thippu Jayaprakash, Kamalram
LUNG CANCER, 2021, 156 : S73 - S74
[22] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
van Veggel, Bianca
de Langen, Adrianus J.
Hashemi, Sayed M. S.
Monkhorst, Kim
Heideman, Danielle A. M.
Thunnissen, Erik
Smit, Egbert F.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
[23] Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab
de la Fuente, Elena Corral
Garcia, Maria Eugenia Olmedo
Martin, Inmaculada Orejana
Berlinches, Amparo Benito
Rueda, Ana Gomez
Alfranca, Yolanda Lage
Garrido, Pilar
CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 5
[24] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Choi, Dae-Ho
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong -Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Lee, Se-Hoon
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
[25] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
Christopoulos, P.
Prawitz, T.
Hong, J-L.
Lin, H. M.
Hernandez, L.
Jin, S.
Tan, M.
Proskorovsky, I.
Lin, J.
Zhang, P.
Patel, J.
Ou, S-H. I.
Thomas, M.
Stenzinger, A.
ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
[26] Will "Sun"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?
Li, Molly
Soo, Ross A.
TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 323 - 327
[27] BUDGET IMPACT ANALYSIS OF INTRODUCING MOBOCERTINIB FOR LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION-POSITIVE NON-SMALL-CELL LUNG CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE
Hernandez, L. G.
Young, M.
VALUE IN HEALTH, 2022, 25 (07) : S364 - S364
[28] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Gao, X.
Wei, X-W.
Wu, Y-L.
Zhou, Q.
ANNALS OF ONCOLOGY, 2019, 30
[29] MATCHING-ADJUSTED INDIRECT COMPARISON OF AMIVANTAMAB VS. MOBOCERTINIB IN EGFR EXON 20 INSERTION-MUTATED NON-SMALL CELL LUNG CANCER
Van Sanden, S.
Rahhali, N.
Schioppa, C.
Diels, J.
Rodrigues, B.
Chandler, C.
Kapetanakis, V
Jain, R.
Li, T.
VALUE IN HEALTH, 2022, 25 (07) : S526 - S526
[30] Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.
Vincent, Sylvie
Su, Zhenqiang
Bunn, Veronica
Joshi, Adarsh
Yu, Ziji
Chatterjee, Sampurna
Guha, Minakshi
Zhang, Pingkuan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →